Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global H
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
07:31am, Tuesday, 12'th May 2026
- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio - - Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expecte
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
07:31am, Tuesday, 12'th May 2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
01:51pm, Thursday, 07'th May 2026
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 07'th May 2026
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wal
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
09:56am, Thursday, 07'th May 2026
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.49 per share a year ago.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 07'th May 2026
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close A
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
11:06am, Thursday, 30'th Apr 2026
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 23'rd Apr 2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on�
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
03:31am, Friday, 17'th Apr 2026
Collegium Pharmaceutical (NASDAQ: COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham and Company's 25th Annual Healt
Collegium to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 08'th Apr 2026
STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Ann
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
09:12pm, Monday, 30'th Mar 2026
6,224 shares were sold for a transaction value of ~$228,000 on March 9, 2026. This sale represented 6.40% of Dieter David's direct holdings prior to the transaction.
Head to Head Contrast: Collegium Pharmaceutical (NASDAQ:COLL) versus electroCore (NASDAQ:ECOR)
02:29am, Sunday, 29'th Mar 2026
electroCore (NASDAQ: ECOR - Get Free Report) and Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
09:59am, Wednesday, 25'th Mar 2026
Scott Dreyer sold 49,976 shares on March 3, 2026, for approximately $2.02 million at a weighted average price of about $40.41 per share. The sale reduced Dreyer's direct holdings by 41.05%, from 121,7
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037
01:02am, Saturday, 21'st Mar 2026
Collegium Pharmaceutical (NASDAQ: COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second
